This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in JAMA

	Since this article does not have an abstract, we have provided the first 124 words of the full text and any section headings.

In Reply: Dr Dettling and colleagues request information about psychiatric comorbidity in the study participants. Diagnoses based on structured interviews were available for 92 of the 93 patients. At the time of randomization, 11 (12.0%) met criteria for a major depressive disorder and 12 (13.0%) met criteria for obsessive-compulsive disorder. These numbers were too small to permit any meaningful statistical analysis and, therefore, were not reported in the article. We concur with the need for additional studies of other pharmacological agents for patients with this challenging illness.

Financial Disclosures: Dr Walsh has reported receiving research support from Eli Lilly and Co, Abbott Laboratories, Ortho-McNeil Pharmaceuticals, and GlaxoSmithKline. Dr Kaplan has reported receiving research support from Eli Lilly and Co. No other authors reported disclosures.

B. Timothy Walsh, MD
btw1@columbia.edu

Christina A. Roberto, BA
Department of Psychiatry
College of Physicians & Surgeons of Columbia University
New York, NY

Allan S. Kaplan, MD, FRCPC; Wendi Rockert, MEd
University of Toronto
Toronto, Ontario

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;296:2440.

RELATED LETTER

Fluoxetine for Treatment of Anorexia Nervosa
Michael Dettling, Carolin Opgen-Rhein, Arnim Quante, and Ion Anghelescu
JAMA. 2006;296(20):2439-2440.
EXTRACT | FULL TEXT